Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16071465 | 0.84 | ADORA2A (0.78) | ADORA2ATHRBKDM4EALDH1A1HPGD | |
| SCHEMBL4515159 | 0.83 | KMT2A (0.51) | KMT2ALMNAMAPT | |
| SCHEMBL4533208 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1 | |
| SCHEMBL8233010 | 0.83 | ADORA2A (0.65) | ADORA2AKDM4ENPSR1KMT2AMEN1 | |
| SCHEMBL8239164 | 0.82 | EGLN1 (0.44) | KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL4520231 | 0.82 | KDM4E (0.48) | KDM4EALDH1A1 | |
| SCHEMBL27724629 | 0.81 | TP53 (0.55) | KDM4EHPGDNPSR1KMT2ALMNA | |
| SCHEMBL13605661 | 0.80 | TP53 (0.45) | KDM4ENPSR1KMT2AMAPT | |
| SCHEMBL8239980 | 0.79 | IKBKB (0.43) | KDM4EALDH1A1 | |
| SCHEMBL13605653 | 0.79 | MAPT (0.58) | ALDH1A1HPGDKMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2009-12-31 | — | — | US | disclosed |
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2009-12-31 | — | — | US | disclosed |
| WO-2007072090-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRIK5 | ADORA2A 485/4885THRB 514/4885PTPN11 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.